The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma

Table 3

Cox proportional hazard models predicting progression-free survival (dependent variable).

	Univariate analysis			Multivariable analysis
	HR	95% CIs	value	HR	95% CIs	value
Gender; (men versus women)	1.20	0.58–2.50	0.62
Age; (each year)	1.00	0.98–1.03	0.70
Surgery; (done versus not done)	0.42	0.14–1.24	0.11
Radiotherapy; (done versus not done)	0.50	0.23–1.10	0.09	0.10	0.03–0.32	0.0003
Chemotherapy; (done versus not done)	0.73	0.33–2.29	0.79
MGMT; (each unit increase)	0.98	0.97–1.01	0.22	0.97	0.94–0.99	0.0025
MGMT; (>19% versus ≤19%)	0.59	0.27–1.28	0.18	0.24	0.10–0.64	0.0045

95% CIs: 95% confidence intervals; HR: hazard ratio.